| 2024-02 |
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study |
The Lancet Oncology
|
| 2024-02 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer |
ESMO Open
|
| 2024-02 |
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06) |
BMC Cancer
|
| 2024-02 |
Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma |
Bioorganic Chemistry
|
| 2024-01 |
Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial |
Nature Communications
|
| 2024-01 |
Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial |
Nature Communications
|
| 2024-01 |
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study |
Journal of Clinical Oncology
|
| 2024-01 |
First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine Against HER2-Positive Advanced Gastric Cancer |
Cancer Research and Treatment
|
| 2024-01 |
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study |
Gastric Cancer
|
| 2023-12 |
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial |
LANCET
|
| 2023-12 |
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer |
Scientific Reports
|
| 2023-11 |
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial |
The Lancet Oncology
|
| 2023-11 |
Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response |
Cell Reports Medicine
|
| 2023-10 |
Impact of Coronavirus Disease 2019 on Gastric Cancer Diagnosis and Stage: A Single-Institute Study in South Korea |
Journal of Gastric Cancer
|
| 2023-10 |
Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study |
Molecular Cancer Therapeutics
|
| 2023-10 |
Cancer coping self-efficacy, symptoms and their relationship with quality of life among cancer survivors |
European Journal of Oncology Nursing
|
| 2023-09 |
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial |
International Journal of Cancer
|
| 2023-09 |
Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy |
Yonsei Medical Journal
|
| 2023-09 |
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer |
Journal of Clinical Oncology
|
| 2023-08 |
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms |
Frontiers in Oncology
|
| 2023-07 |
Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer |
Clinical Chemistry and Laboratory Medicine
|
| 2023-07 |
Immunogenicity and Safety of Vaccines Against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study |
Cancer Research and Treatment
|
| 2023-06 |
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform |
Oncologist
|
| 2023-06 |
Care Needs of Adolescents and Young Adults with Cancer Undergoing Active Treatment in South Korea: A Mixed Methods Study |
Journal of Adolescent and Young Adult Oncology
|
| 2023-05 |
PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma |
Nature Cell Biology
|
| 2023-04 |
Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20) |
Cancer Research and Treatment
|
| 2023-04 |
High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma |
JHEP Reports
|
| 2023-03 |
Risk factors for delirium among patients with advanced cancer in palliative care: a multicenter, patient-based registry cohort in South Korea |
European Review for Medical and Pharmacological Sciences
|
| 2023-03 |
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study |
HEPATOLOGY
|
| 2023-03 |
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study |
The Lancet Oncology
|
| 2023-02 |
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG) |
BMC Cancer
|
| 2023-01 |
Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea |
Palliative Medicine Reports
|
| 2023-01 |
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma |
ONCOLOGIST
|
| 2023-01 |
Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination |
Journal of Gastric Cancer
|
| 2023-01 |
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer |
The New England journal of medicine
|
| 2022-12 |
Enhanced supportive care for advanced cancer patients: study protocol for a randomized controlled trial |
BMC Nursing
|
| 2022-12 |
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study |
The Lancet Oncology
|
| 2022-12 |
Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden |
Clinical chemistry
|
| 2022-11 |
Understanding the Social Mechanism of Cancer Misinformation Spread on YouTube and Lessons Learned: Infodemiological Study |
Journal of medical Internet research
|
| 2022-10 |
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer |
NATURE COMMUNICATIONS
|
| 2022-10 |
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors |
Investigational New Drugs
|
| 2022-09 |
The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients |
Genomics and Informatics
|
| 2022-09 |
Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy |
Cancers
|
| 2022-09 |
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial |
European Urology
|
| 2022-09 |
Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer |
EUROPEAN JOURNAL OF CANCER
|
| 2022-08 |
Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma |
CLINICAL CANCER RESEARCH
|
| 2022-07 |
PD-L1 expression and overall survival in Asian and western patients with gastric cancer |
FUTURE ONCOLOGY
|
| 2022-07 |
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition |
GUT
|
| 2022-06 |
Fear of cancer recurrence and its predictors and outcomes among cancer survivors: A descriptive correlational study |
EUROPEAN JOURNAL OF ONCOLOGY NURSING
|
| 2022-06 |
Self-efficacy for coping with cancer and quality of life in advanced gastric cancer patients |
EUROPEAN JOURNAL OF ONCOLOGY NURSING
|
| 2022-06 |
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study |
LANCET ONCOLOGY
|
| 2022-05 |
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) |
Gastric Cancer
|
| 2022-05 |
Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin |
Cancers
|
| 2022-04 |
Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer |
CANCER DISCOVERY
|
| 2022-04 |
The Essentials of Multiomics |
ONCOLOGIST
|
| 2021-12 |
Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer |
CELLULAR ONCOLOGY
|
| 2021-12 |
Prognostic significance of T-cell–inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer |
CANCER MEDICINE
|
| 2021-10 |
International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1) |
Annals of Gastroenterological Surgery
|
| 2021-10 |
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma |
ONCOLOGIST
|
| 2021-10 |
Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial |
ESMO OPEN
|
| 2021-10 |
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations |
INVESTIGATIONAL NEW DRUGS
|
| 2021-09 |
PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer |
JOURNAL OF CLINICAL ONCOLOGY
|
| 2021-09 |
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) |
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
|
| 2021-05 |
3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy |
CANCER RESEARCH
|
| 2021-05 |
SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence |
GASTRIC CANCER
|
| 2021-05 |
Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population |
GUT
|
| 2021-05 |
Detection of asymptomatic recurrence improves survival of gastric cancer patients |
CANCER MEDICINE
|
| 2021-04 |
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma |
NEW ENGLAND JOURNAL OF MEDICINE
|
| 2021-04 |
Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea |
CANCER RESEARCH AND TREATMENT
|
| 2021-03 |
Stable Symptom Clusters and Evolving Symptom Networks in Relation to Chemotherapy Cycles |
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
|
| 2021-02 |
Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis |
EUROPEAN JOURNAL OF CANCER
|
| 2021-01 |
Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing |
FRONTIERS IN PHARMACOLOGY
|
| 2021-01 |
p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer |
BIOCHEMICAL PHARMACOLOGY
|
| 2020-12 |
Transcriptome analysis of IBET-151, a bet inhibitor alone and in combination with paclitaxel in gastric cancer cells |
Genomics & Informatics
|
| 2020-09 |
Cross-species chromatin interactions drive transcriptional rewiring in Epstein-Barr virus-positive gastric adenocarcinoma |
NATURE GENETICS
|
| 2020-09 |
Scale-up evaluation of a composite tumor marker assay for the early detection of renal cell carcinoma |
Diagnostics
|
| 2020-09 |
Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells |
FRONTIERS IN ONCOLOGY
|
| 2020-08 |
Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer |
Molecular therapy oncolytics.
|
| 2020-07 |
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma |
JOURNAL OF CLINICAL ONCOLOGY
|
| 2020-07 |
Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells |
YONSEI MEDICAL JOURNAL
|
| 2020-03 |
Unmet needs in the physical and daily living domain mediates the influence of symptom experience on the quality of life of gastric cancer patients |
SUPPORTIVE CARE IN CANCER
|
| 2020-02 |
Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)-a randomized controlled trial |
SUPPORTIVE CARE IN CANCER
|
| 2019-12 |
Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function |
Journal for ImmunoTherapy of Cancer
|
| 2019-11 |
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium |
European Urology Oncology
|
| 2019-11 |
Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer |
ONCOLOGIST
|
| 2019-11 |
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. |
GASTRIC CANCER
|
| 2019-11 |
Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer |
GASTRIC CANCER
|
| 2019-10 |
Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer |
Journal for ImmunoTherapy of Cancer
|
| 2019-10 |
Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea |
CANCER RESEARCH AND TREATMENT
|
| 2019-10 |
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. |
CANCER RESEARCH AND TREATMENT
|
| 2019-07 |
Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma. |
YONSEI MEDICAL JOURNAL
|